Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Breast Cancer Cell Lines
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Epidermal Growth Factor Receptor
100%
Synergistic Inhibition
100%
Bcl-2 Inhibitor
100%
Dual Inhibitor
100%
Lapatinib
66%
B-cell Lymphoma 2 (Bcl-2)
33%
MCF-7
33%
MCF-7 Cells
33%
Human Tumors
33%
HA14-1
33%
Receptor Tyrosine Kinase
33%
Human Breast Cancer Cell Lines
33%
ErbB
33%
GX15-070
33%
Clinical Trials
16%
Advanced Cancer Patients
16%
Covalent Inhibitor
16%
Human Breast Cancer Cells
16%
Overexpression
16%
Cancer Cells
16%
Clinical Response
16%
Breast Cancer Patients
16%
Antiproliferative Activity
16%
Bcl-2 Family Proteins
16%
Induced Apoptosis
16%
Pharmacokinetics
16%
Poor Prognosis
16%
Anti-apoptotic Proteins
16%
Tyrosine Kinase Inhibitor
16%
ErbB1
16%
Heavily Pretreated
16%
ErbB2
16%
Tyrosine Kinase 2 (TYK2)
16%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Epidermal Growth Factor Receptor
100%
Lapatinib
66%
Neoplasm
33%
Protein Tyrosine Kinase
33%
2 Amino 6 Bromo 4 (1 Cyano 2 Ethoxy 2 Oxoethyl) 4h Chromene 3 Carboxylic Acid Ethyl Ester
33%
Obatoclax
33%
Malignant Neoplasm
16%
Receptor
16%
Tamoxifen
16%
Clinical Trial
16%
Advanced Cancer
16%
Antiapoptotic
16%
Protein Tyrosine Kinase Inhibitor
16%
Tetrazolium
16%
Pharmacokinetics
16%